Evaluating of the Hospital Universitario de Canarias Massive Transfusion Protocol
キーワード
概要
日付
最終確認済み: | 02/28/2017 |
最初に提出された: | 12/21/2016 |
提出された推定登録数: | 03/04/2017 |
最初の投稿: | 03/08/2017 |
最終更新が送信されました: | 03/04/2017 |
最終更新日: | 03/08/2017 |
実際の研究開始日: | 12/31/2014 |
一次完了予定日: | 05/31/2017 |
研究完了予定日: | 07/31/2017 |
状態または病気
介入/治療
Device: Intervention (cases)
段階
アームグループ
腕 | 介入/治療 |
---|---|
Experimental: Intervention (cases) Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors | Device: Intervention (cases) Application lMassive Transfusion Protocol |
No Intervention: No Intervention (control)) all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply |
適格基準
研究の対象となる年齢 | 18 Years に 18 Years |
研究に適格な性別 | All |
健康なボランティアを受け入れる | はい |
基準 | Inclusion Criteria: - Patients with massive haemorrhage and surgery - Informed consent Exclusion Criteria: - <18 years old patients - Patients didn´t want to participate in this study - Patients were participated in other studies |
結果
主な結果の測定
1. 30-day Mortality [First 30 day after massive transfusion]
2. Time to Hemostasis [admission to hospital discharge or 30 days, whichever comes first]
二次的な結果の測定
1. Incidence of Massive Transfusion Related Serious Adverse Events [30 days]
2. Severity of coagulopathy associated with high transfusion ratios [30 days post admission]
3. Amount of Blood Products Given to Hemostasis [24 hours from randomization]
4. Amount of Blood Products Given From Hemostasis to 24 Hours After [24 hours after admission]